Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817670 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by Vifor (International).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 20
- Study locations
NCT04817670 is a Phase 2 study of Sickle Cell Disease that has completed, run by Vifor (International). The registered enrollment target is 25 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04817670, a Phase 2 study of Sickle Cell Disease, has completed, sponsored by Vifor (International).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD). The safety, tolerability and clinical beneficial effects of VIT-2763 for the treatment of SCD are also explored.
Conditions Studied
Interventions
- DRUG Placebo BID
- DRUG VIT-2763 120 mg
- DRUG VIT-2763 360 mg
- DRUG VIT-2763 240 mg
- DRUG Placebo TID
Study Locations (20)
Other
- Investigator Site 801 - Colombes
- Investigator Site 802 - Lyon
- Investigator Site 305 - Athens
- Investigator site 301 - Athens
- Investigator Site 302 - Pátrai
- Investigator Site 101 - Baabda
- Investigator Site 102 - Beirut
- Investigator Site 103 - Tripoli
- Investigator Site 606 - Liverpool
- Investigator Site 603 - London
- Investigator Site 608 - London
- Investigator Site 601 - London
Alabama
- Investigator Site 709 - Birmingham
California
- Investigator Site 708 - Los Angeles
Colorado
- Investigator Site 713 - Aurora
Florida
- Investigator Site 706 - Hollywood
Illinois
- Investigator Site 703 - Chicago
North Carolina
- Investigator Site 701 - Greenville
South Carolina
- Investigator Site 711 - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04817670
The ClinicalTrials.gov registry entry for NCT04817670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The listed sponsor is Vifor (International), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo BID is the first listed.
NCT04817670 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04817670 about?
NCT04817670 is a clinical study titled "Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease". The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD). The safety, tolerability and clinical beneficial effects of VIT-2763 for the treatment of SCD are also explored.
What is the current status of trial NCT04817670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-11-18. Estimated completion is 2024-03-07.
What conditions does trial NCT04817670 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04817670?
The interventions under investigation include: Placebo BID (DRUG), VIT-2763 120 mg (DRUG), VIT-2763 360 mg (DRUG), VIT-2763 240 mg (DRUG), Placebo TID (DRUG).
Who is sponsoring clinical trial NCT04817670?
This trial is sponsored by Vifor (International), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04817670 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.